Navigation Links
YM BioSciences Reports AeroLEF Randomized Phase IIb Trial Meets,Primary Endpoint in Patients with Post-Surgical Pain

an, Chairman and CEO of YM BioSciences. "We look forward to completing a detailed analysis of the numerous secondary endpoints and safety data from this study to extend the information we will make available. These results will also be used to enhance the design of the additional Phase II trial that we are planning for the U.S. as well as the eventual Phase III trial."

Clinical Trial Design

The Phase IIb clinical study (DLXLEF-AP4) was a 2-part, multi-center study to evaluate the efficacy, safety and tolerability of repeated, self-titrated inhalation of AeroLEF(TM) for the treatment of acute post-operative pain following orthopedic surgery. Part 1 of the study was a 21 patient open-label, lead-in study to ensure consistency of AeroLEF(TM) administration across study sites. Results of Part I of the Phase IIb study were presented at the 2006 American Society of Anesthesiologists (ASA) Annual Meeting in Chicago, IL.

Part 2 was a 99 patient randomized, placebo-controlled study. The treatment phase of the study began in the post-anesthetic care unit (PACU) after completion of surgery when the patient reported a pain intensity score (PI) of at least 2 (moderate pain) on a 4-point verbal rating scale (0 (none) to 3 (severe pain)). The clinical trial study period was up to 12 hours and patients were allowed to self-administer AeroLEF(TM) to treat up to two additional pain episodes during the study period.

About YM BioSciences

YM BioSciences Inc. is an oncology company that identifies, develops and commercializes differentiated products for patients worldwide. The Company has two late-stage products: nimotuzumab, a humanized monoclonal antibody that targets the epidermal growth factor receptor (EGFR) and is approved in several countries for treatment of various types of head and neck cancer; and AeroLEF(TM), a unique, inhaled-delivery composition of free and liposome-encapsulated fentanyl in development for the treatment of moderate to seve
'"/>




Page: 1 2 3

Related medicine technology :

1. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
2. YM BioSciences Announces Preclinical Data Confirming Nimotuzumab Binds to the EGF Receptor and Potentiates Radiotherapy
3. Sangamo BioSciences Announces Presentation of Phase 1 ZFP Therapeutic Data at American Diabetes Association Meeting
4. IR BioSciences Announces Promising Data from Study of Its Compound Homspera
5. Sangamo BioSciences Announces Presentation of ZFP Therapeutic Data From Nerve Regeneration Program at American Society for Neural Therapy and Repair Meeting
6. ImmuneRegen BioSciences Announces Promising Data on Homspera Suggesting Potential as a Co-Therapeutic Agent
7. Study in Cell by Magen BioSciences Co-Founder David E. Fisher Identifies New Roles in Skin Cancer Prevention for Key Tumor Suppressor Protein
8. IR BioSciences Announces Data Demonstrating Radilex Stimulation of Stem Cells Results in Hematopoietic Recovery Following Lethal Irradiation
9. Corgenix Reports New Clinical Data Correlating AtherOx Technology With Vascular Disease
10. Cobalis Reports Phase III Trial Results for PreHistin in Seasonal Allergic Rhinitis
11. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
Post Your Comments:
(Date:5/1/2015)... 2015 Braeburn Pharmaceuticals announced today ... focus beyond addiction and pain to include ... has acquired an implantable, six-month formulation of ... treatment of schizophrenia from Endo Pharmaceuticals. With ... to other potential applications of the implant ...
(Date:5/1/2015)... Semler Scientific, Inc. (Nasdaq: SMLR ), ... and markets products that assist healthcare providers in monitoring ... for the first quarter ended March 31, 2015. ... reported continued progress with year over year growth of ... 14%," said Doug Murphy-Chutorian , M.D., chief executive ...
(Date:4/30/2015)... , April 30, 2015 /PRNewswire/ - Pivotal Therapeutics ... company with a focus on Omega-3 therapies for ... operational highlights and financial results for the fiscal ... referenced herein are in Canadian dollars unless otherwise ... been significant, with the right strategic partners and ...
Breaking Medicine Technology:Braeburn Pharmaceuticals expands pipeline to include two schizophrenia treatments 2Braeburn Pharmaceuticals expands pipeline to include two schizophrenia treatments 3Braeburn Pharmaceuticals expands pipeline to include two schizophrenia treatments 4Semler Reports First Quarter 2015 Financial Results 2Semler Reports First Quarter 2015 Financial Results 3Semler Reports First Quarter 2015 Financial Results 4Semler Reports First Quarter 2015 Financial Results 5Pivotal Therapeutics Announces 2014 Financial Results 2Pivotal Therapeutics Announces 2014 Financial Results 3Pivotal Therapeutics Announces 2014 Financial Results 4Pivotal Therapeutics Announces 2014 Financial Results 5Pivotal Therapeutics Announces 2014 Financial Results 6
(Date:5/3/2015)... 03, 2015 Leading international program provider, ... will be awarding the 2015 Harris Wofford Global Service ... Ghebrendrias, are the deserving recipients of the award named ... Harris Llewellyn Wofford. The two recipients were chosen for ... global health. , CFHI is one of seven ...
(Date:5/3/2015)... (PRWEB) May 03, 2015 NuevaCare announced ... at two upcoming area seminars. The first event will ... Annual Regional Stroke Conference to be held at The ... on Wednesday, May 13 during the Dementia Conference to ... , “These seminars offer an excellent opportunity to learn ...
(Date:5/2/2015)... Ticket Down has secured additional inventories of authentic ... event today, Saturday, May 2nd at the MGM Grand Garden ... able to secure tickets for both the actual fight and ... have wanted for more than five years was finally been ... step inside the ring to fight Manny “Pac-Man” Pacquiao in ...
(Date:5/2/2015)... May 02, 2015 We are pleased ... Delray Recovery Center as one of the Top Workplaces ... in the addiction treatment field for their ethics and ... innovate and to continue their educational efforts. The Delray ... environment, never forgetting their purpose – to help individuals ...
(Date:5/2/2015)... Portland, OR (PRWEB) May 02, 2015 ... that it has submitted plans to offer its new ... Oregon Exchange. The ZOOM+ Personal Health Insurance System is ... ground up to enhance human performance. ZOOM+ Personal Health ... a healthcare delivery system that are subject to review ...
Breaking Medicine News(10 mins):Health News:SF-based Global Health Non-Profit Awards Harris Wofford Global Service Fellowship 2Health News:SF-based Global Health Non-Profit Awards Harris Wofford Global Service Fellowship 3Health News:NuevaCare Introduces MnemeTherapy® Approach to Care for Elderly Patients with Alzheimer’s, Stroke and Other Types of Neurodegenerative Conditions 2Health News:Cheap Floyd Mayweather vs. Manny Pacquiao Tickets: Ticket Down Has Last Minute Tickets for Mayweather vs. Pacquiao at the MGM Grand Garden Arena in Las Vegas 2Health News:Cheap Floyd Mayweather vs. Manny Pacquiao Tickets: Ticket Down Has Last Minute Tickets for Mayweather vs. Pacquiao at the MGM Grand Garden Arena in Las Vegas 3Health News:The Delray Recovery Center Named 2015 Top Workplace 2Health News:ZoomCare Applies to be on Oregon Exchange 2
... District Sickens 32 , , ... outbreak in the West Middlesex Area School District, the Pennsylvania ... School and West Middlesex Junior/Senior High School on Nov. 19 ... The tetanus/diphtheria/pertussis vaccine was given to approximately 560 ...
... star, and daughter of NBA power couple Doug and Jackie Christie, ... 2008 which is World AIDS,Day. To kick off her new charity ... Live: A Teenager,s Guide To Finding Self Love, to youth,across the ... "It is an honor to ...
... those with poor glucose control likely to have artery disease ... earlier research, a new study has identified a genetic ... in type 2 diabetes patients with poor sugar glucose (glycemic) ... on a genetic chromosome known as chromosome 9p21 are ...
... risks, benefits, experts say , , TUESDAY, Nov. 25 (HealthDay ... that some common inhalers don,t boost the life spans ... obstructive pulmonary disease (COPD). , In fact, these medicines ... with COPD, the fourth biggest killer in the United ...
... the added pounds, not impaired detection, that,s to blame, study ... boosts the risk of getting advanced breast cancer for older ... than 287,000 women and took into account their mammogram habits. ... risk, the researchers concluded. , "Women who are above ...
... Conference Commits to Increase Coverage of African American Health Issues ... The National Association of Black Journalists (NABJ) will present ... Morehouse School of Medicine in Atlanta. This conference ... to better train our journalists on the increasing number of ...
Cached Medicine News:Health News:Teen Pop Star, Chantel 'Chani' Christie, Launches the Chani Girl Foundation to Bring Education/Awareness on HIV/AIDS 2Health News:Chromosome Linked to Diabetics' Heart Risks 2Health News:Steroid Inhalers Raise Pneumonia Risk for Lung Disease Patients 2Health News:Steroid Inhalers Raise Pneumonia Risk for Lung Disease Patients 3Health News:Weight Boosts Older Women's Breast Cancer Risk 2Health News:Weight Boosts Older Women's Breast Cancer Risk 3Health News:Black Journalists to Host Conference on Health Disparities 2
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: